Federated Hermes Inc. Boosts Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Federated Hermes Inc. increased its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 14.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,883,775 shares of the company’s stock after purchasing an additional 500,046 shares during the period. Federated Hermes Inc. owned approximately 6.03% of IDEAYA Biosciences worth $138,185,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in IDYA. Swiss National Bank increased its holdings in IDEAYA Biosciences by 7.8% in the first quarter. Swiss National Bank now owns 63,800 shares of the company’s stock valued at $714,000 after buying an additional 4,600 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of IDEAYA Biosciences by 23.9% in the first quarter. JPMorgan Chase & Co. now owns 20,058 shares of the company’s stock valued at $224,000 after purchasing an additional 3,870 shares during the last quarter. MetLife Investment Management LLC grew its position in shares of IDEAYA Biosciences by 58.5% in the first quarter. MetLife Investment Management LLC now owns 17,271 shares of the company’s stock valued at $193,000 after purchasing an additional 6,374 shares during the last quarter. Rhumbline Advisers grew its position in shares of IDEAYA Biosciences by 4.8% in the first quarter. Rhumbline Advisers now owns 39,982 shares of the company’s stock valued at $447,000 after purchasing an additional 1,835 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of IDEAYA Biosciences by 56.2% in the first quarter. Dimensional Fund Advisors LP now owns 425,183 shares of the company’s stock valued at $4,758,000 after purchasing an additional 153,022 shares during the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at IDEAYA Biosciences

In other news, insider Briseno Andres Ruiz sold 2,000 shares of the firm’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $42.03, for a total value of $84,060.00. Following the transaction, the insider now owns 26,531 shares of the company’s stock, valued at approximately $1,115,097.93. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Briseno Andres Ruiz sold 2,000 shares of the firm’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $42.03, for a total value of $84,060.00. Following the transaction, the insider now owns 26,531 shares of the company’s stock, valued at approximately $1,115,097.93. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Yujiro S. Hata sold 23,557 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the completion of the transaction, the chief executive officer now directly owns 677,887 shares in the company, valued at approximately $30,870,973.98. The disclosure for this sale can be found here. Insiders have sold a total of 27,557 shares of company stock worth $1,248,886 in the last quarter. 5.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on IDYA shares. BTIG Research started coverage on shares of IDEAYA Biosciences in a research report on Friday, March 8th. They issued a “buy” rating and a $55.00 price target on the stock. The Goldman Sachs Group increased their price target on shares of IDEAYA Biosciences from $36.00 to $53.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Royal Bank of Canada increased their price target on shares of IDEAYA Biosciences from $43.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday, February 21st. Citigroup increased their price target on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, March 21st. Finally, JPMorgan Chase & Co. increased their price target on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Thirteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $44.55.

IDEAYA Biosciences Stock Down 3.6 %

Shares of IDYA traded down $1.45 during mid-day trading on Thursday, reaching $38.72. The company had a trading volume of 172,258 shares, compared to its average volume of 848,319. The firm has a fifty day simple moving average of $44.19 and a 200-day simple moving average of $36.93. IDEAYA Biosciences, Inc. has a fifty-two week low of $14.33 and a fifty-two week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, February 20th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The company had revenue of $3.90 million during the quarter, compared to analyst estimates of $8.84 million. IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 23.00%. The company’s revenue was down 3.0% on a year-over-year basis. Analysts forecast that IDEAYA Biosciences, Inc. will post -2.26 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.